This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
ANNUAL REPORT AND ACCOUNTS POSTED TO SHAREHOLDERS
NOTICE OF ANNUAL GENERAL MEETING ON 28 JUNE 2018 @ 10.30 AM
VENUE: SKY LIGHT CITY TOWER, 50 BASINGHALL STREET, LONDON, EC2
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2017 has been posted to shareholders.
This report includes the 'Annual Report of the Annual General Meeting' ('AGM') as well as the 'Notice of the 2018 AGM', which will be available later today, in electronic form, for download on the Company's website www.immupharma.org.
ImmuPharma's AGM will be held on Thursday 28 June at 10:30am at Sky Light City Tower, 50 Basinghall Street, EC2V 5DE.
-Ends-
|
|
|
For further information please contact:
ImmuPharma plc (www.immupharma.co.uk) |
+ 44 (0) 20 7152 4080 |
Tim McCarthy, Chairman |
|
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma |
+ 44 (0) 7721 413496 |
|
|
Northland Capital Partners Limited (NOMAD & Joint Broker) David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking |
+44 (0)20 3861 6625 |
|
|
|
|
Bryan, Garnier & Co. (Joint Broker) +44 (0)20 7332 2500 Phil Walker, Corporate Finance Dominic Wilson, Sales |
|
| |
|
|
|
|